OneCell Diagnostics Raises $16 Million for Cancer Testing

OneCell Diagnostics, a cancer diagnostics startup, has successfully raised $16 million in an oversubscribed Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The funding will be utilized to expand its innovative liquid biopsy test, OncoIndx Alfa, into the U.S. market, enhancing precision oncology by detecting circulating tumor cells and offering advanced biomarkers for cancer diagnosis and treatment. CEO Mohan Uttarwar emphasized the company's vision of democratizing access to life-saving cancer testing through advanced technology integrating single-cell multi-omics analytics. OneCell has already tested nearly 10,000 patients in India and aims to replicate this success in the U.S. market. Additionally, the company has partnered with notable institutions like Harvard Medical School and Tata Memorial Centre. The funding round will also see prominent figures like Michael Marks and James Rothman join the OneCell board of directors.